



Supplementary Fig. 12. Clinical case studies of feladilimab monotherapy and in combination with pembrolizumab. (a) CT imaging of tumor lesions for a patient with metastatic nodular melanoma who received feladilimab monotherapy at 1 mg/kg followed by 3 mg/kg to week 48 (patient presented in **Supplementary Fig 11a, b). (b) CT imaging of**

tumor lesions for the patient with oropharyngeal squamous cell carcinoma who received feladilimab at 0.3 mg/kg + pembrolizumab 200 mg Q3W to week 30 (patient presented in **Fig. 5a, c**).